Epidemiologic comparison of the first and second waves of coronavirus disease in Babol, North of Iran.

PubMed, Journal Year: 2020, Volume and Issue: 11(Suppl 1), P. 544 - 550

Published: Jan. 1, 2020

A few studies compared the epidemiologic features of first and second waves coronavirus disease 2019 (COVID-19) outbreak. This research was carried out to compare 1st 2nd epidemics in northern Iran.In this observational research, demographic, clinical laboratory characteristics patients with COVID-19, admitted four government hospitals affiliated Babol University Medical Sciences during COVID-19 have been compared. The period from May 21, 2020 September considered as wave while February 19, 20, 2020, outbreak region.Out 6691 total hospitalized cases, 4374 (65.37%), including 1532 (49.6%) people 2842 (78.9%) had RT-PCR test for confirmation. Among those who were examined test, 2322 (53.1%) 728 (31.4%) persons 1594 (68.6%) positive SARS-CoV-2 RNA. 414 (56.9%) confirmed cases 767 (48.1%) males (p<0.001). Gastrointestinal symptoms more incidental disease. However, severe respiratory conditions common Crude mortality rate lower (p<0.001).Different found comparison northerrn Iran.

Language: Английский

---

SARS-CoV-2 and Viral Sepsis: Immune Dysfunction and Implications in Kidney Failure

Journal of Clinical Medicine, Journal Year: 2020, Volume and Issue: 9(12), P. 4057 - 4057

Published: Dec. 15, 2020

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causal agent of disease 2019 (COVID-19), first emerged in Wuhan, China. The clinical manifestations patients infected with COVID-19 include fever, cough, and dyspnea, up to distress (ARDS) cardiac injury. Thus, a lot severe had be admitted intensive care units (ICU). pathogenic mechanisms SARS-CoV-2 infection are mediated by binding spikes human angiotensin-converting enzyme (ACE-2) receptor. overexpression ACE-2 is associated severity infection, demonstrating that viral entry into cells pivotal step. Although lung organ most commonly affected kidney injury (AKI), heart dysfunction abdominal pain reported co-morbidities COVID-19. occurrence AKI might explained several cytopathic effects renal host hyperinflammatory response. In addition, could exacerbate inflammatory response started lungs cause further impairment multi-organ failure. Mounting recent evidence supports involvement cardiovascular complications endothelial syndrome, addition disease. To date, there no vaccine, specific antiviral medicine has been shown effective preventing or treating removal pro-inflammatory cytokines shutdown cytokine storm ameliorate outcome cases. Therefore, interventions inhibit replication systemic modulate increase probability favorable outcome.

Language: Английский

---

Hemoperfusion and blood purification strategies in patients with COVID‐19: A systematic review

Artificial Organs, Journal Year: 2021, Volume and Issue: 45(12), P. 1466 - 1476

Published: Oct. 10, 2021

Abstract Background Coronavirus disease‐19 (COVID‐19) ranges from asymptomatic infection to severe cases requiring admission the intensive care unit. Together with supportive therapies (ventilation in particular), suppression of pro‐inflammatory state has been a hypothesized target. Pharmacological corticosteroids and interleukin‐6 (IL‐6) receptor antagonists have reduced mortality. The use extracorporeal cytokine removal, also known as hemoperfusion (HP), could be promising non‐pharmacological approach decrease COVID‐19. Methods We conducted systematic review PubMed EMBASE databases order summarize evidence regarding HP therapy included original studies case series enrolling at least five patients. Results 11 articles describe characteristics populations studied both clinical biological perspectives. methodological quality was generally low. Only two had control group, one which 101 patients total. remaining range between 10 50 included. There large variability techniques implemented outcomes reported. Most described decreasing levels IL‐6 after treatment. Conclusion Our does not support strong conclusions role Considering very low level detected, starting COVID‐19 seem supported outside trials. Prospective randomized data are needed.

Language: Английский

---

Extracorporeal Blood Purification in Moderate and Severe COVID-19 Patients: A Prospective Cohort Study

Blood Purification, Journal Year: 2021, Volume and Issue: 51(3), P. 233 - 242

Published: June 14, 2021

Coronavirus disease 2019 (COVID-19) is characterized by hyperinflammation and coagulopathy. Severe cases often develop respiratory distress, requiring mechanical ventilation with critical progressing to acute distress syndrome. Control of has been proposed as a possible therapeutic avenue for COVID-19; extracorporeal blood purification (EBP) modalities offer an attractive mean ameliorate maladaptive inflammation. With this work, we evaluated the longitudinal changes systemic inflammatory markers in critically ill COVID-19 patients treated using AN69ST (oXiris®) haemofilter.We performed time-series analysis 44 consecutive cytokine adsorbing haemofilter (CAH) according local practice; visualize results biochemical, inflammatory, gas, vital sign parameters focussing on levels interleukin-6 (IL-6), C-reactive protein (CRP), procalcitonin.All were ≥1 cycle continuous venovenous haemofiltration (CVVH) CAH; these, 30 severe received CVVH-CAH within 4-12 h admission after recognizing hyper-inflammatory state. Another 14 admitted mild-to-moderate symptoms progressed placed EBP during hospitalization. The treatment was associated reduction ferritin, CRP, fibrinogen, several markers, resolution numerous cytopenias. observed mortality across cohort 36.3%.EBP CAH decrease control IL-6 procalcitonin.

Language: Английский

---

COVID-19 in Chronic Kidney Disease: The Impact of Old and Novel Cardiovascular Risk Factors

Blood Purification, Journal Year: 2021, Volume and Issue: 50(6), P. 740 - 749

Published: Jan. 1, 2021

Cardiovascular disease is a frequent complication and the most common cause of death in patients with CKD. Despite landmark medical advancements, mortality due to cardiovascular still 20 times higher CKD than general population, which mainly high prevalence risk factors this group. Indeed, addition traditional factors, are exposed nontraditional ones, include metabolic, hormonal, inflammatory alterations. The global severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has brought novel challenges for both cardiologists nephrologists alike. Emerging evidence indicates that 2019 (COVID-19) increases events several aspects may synergize pre-existing patients. A better understanding these mechanisms pivotal prevention treatment context, we believe additional clinical experimental studies needed improve outcomes COVID-19. In review, provide summary patients, discussing their interaction SARS-CoV-2 infection focusing on CO­VID-19-related complications severely affect short- long-term high-risk population.

Language: Английский

---

Investigation of plasma exchange and hemoperfusion effects and complications for the treatment of patients with severe COVID‐19 (SARS‐CoV‐2) disease: A systematic scoping review

Journal of Medical Virology, Journal Year: 2021, Volume and Issue: 93(10), P. 5742 - 5755

Published: July 6, 2021

Abstract Some previous studies suggested that the plasma exchange (PE) and hemoperfusion (HP) played a cardinal role in treatment of severe coronavirus disease 2019 (COVID‐19) cases by diminishing cytokine storm. This study aimed to assess effects PE HP on storms patients with COVID‐19 through systematic scoping review. Four Electronic databases (Medline [accessed from PubMed], Scopus, Science Direct, Cochrane library) were searched systematically February 2, 2021, using MESH terms related keywords English language. Considering titles abstracts, unrelated excluded. The full texts remained evaluated authors, independently. Then, their findings assessed reported. A total 755 articles obtained within first step searching, 518 after removing duplications. Through title abstract screening, 438 removed. Of rest, 59 papers Finally, reading text articles, 21 included data extraction. Most previously reported evidence case reports series. Findings summarized two categories. category encompassed nine regarding continuous renal replacement therapy, second twelve about PE. results revealed storm phase would be beneficial high probability severely ill patients. Highlights showed an important disease. this review

Language: Английский

---

Synthesis, characterization, radical scavenging properties of zinc oxide nanoparticles and inhibitory effect of ZnONPs-ciprofloxacin nanoconjugates on multidrug-resistant Staphylococcus aureus (MRSA) enzyme

Inorganic Chemistry Communications, Journal Year: 2023, Volume and Issue: 160, P. 111864 - 111864

Published: Dec. 19, 2023

Language: Английский

---

The effect of hemoperfusion on the outcome, clinical and laboratory findings of patients with severe COVID-19: a retrospective study

New Microbes and New Infections, Journal Year: 2021, Volume and Issue: 44, P. 100937 - 100937

Published: Sept. 2, 2021

Hemoperfusion is a method of blood filtering to remove toxins and inflammatory factors. Cytokine storms high levels factors play role in the pathogenesis coronavirus disease 2019 (COVID-19). The present study aims evaluate effect hemoperfusion on clinical laboratory findings outcomes patients with severe COVID-19. Forty-eight COVID-19 positive PCR test, who were admitted intensive care unit (ICU), participated study. All treated by routine treatment protocol for was performed 24 addition conventional antiviral therapies. other made up control group. Demographic data, patient before after retrospectively collected analysed. There no significnt difference mortality or length hospital stays between group breathing rate (P-vaalue = 0.001) heart beat (P-value 0.028) decreased hemoperfusion. resulted significant increase SpO2 decrease CRP compared 0.009). can improve respiratory distress. It reduce but has mortality.

Language: Английский

---

Treatment of acute kidney injury with continuous renal replacement therapy and cytokine adsorber (CytoSorb®) in critically ill patients with COVID‐19

Therapeutic Apheresis and Dialysis, Journal Year: 2024, Volume and Issue: 28(6), P. 941 - 950

Published: July 3, 2024

This retrospective study aimed to evaluate the 30 and 60-day survival of critically ill patients with COVID-19 AKI.

Language: Английский

---

Blood filtering system for COVID-19 management: novel modality of the cytokine storm therapeutics

Frontiers in Immunology, Journal Year: 2023, Volume and Issue: 14

Published: April 21, 2023

The newly emerged coronavirus (SARS-CoV-2) is virulent, contagious, and has rapidly gained many mutations, which makes it highly infectious swiftly transmissible around the world. SARS-CoV-2 infects people of all ages targets body organs their cellular compartments, starting from respiratory system, where shows deleterious effects, to other tissues organs. Systemic infection can lead severe cases that require intensive intervention. Multiple approaches were elaborated, approved, successfully used in intervention infection. These range utilization single and/or mixed medications specialized supportive devices. For critically ill COVID-19 patients with acute distress syndrome, both extracorporeal membrane oxygenation (ECMO) hemadsorption are utilized combination or individually support release etiological factors responsible for “cytokine storm” underlying this condition. current report discusses devices be as part treatment COVID-19-associated cytokine storm.

Language: Английский

---